The Korean Journal of Gastroenterology (대한소화기학회지)

The Korean Society of Gastroenterology (대한소화기학회)
권호 표지
DOI QR코드

DOI QR Code

Helicobacter pylori Eradication Therapy and Gastric Cancer Prevention

헬리코박터 제균 치료와 위암 예방

  • Choi, Il Ju (Center for Gastric Cancer, National Cancer Center)
  • Received : 2018.10.17
  • Accepted : 2018.10.29
  • Published : 2018.11.25
⟨ Previous Next ⟩

Abstract

Gastric cancer is the most common cancer in Korea and the fifth most common cancer globally. Helicobacter pylori (H. pylori) infection is considered the main etiologic agent for gastric cancer development. Most regional guidelines for H. pylori treatment recommend treating the organism to prevent gastric cancer in the high-risk group. However, evidence that such a strategy can also be applied to the general population, especially in terms of the preventive effect and safety, has not been adequately presented yet. Although a meta-analysis in the general population suggested effectiveness in decreasing gastric cancer incidence, individual studies should be critically reviewed to evaluate the soundness of the evidence. Recently published, long-term, Korean studies on metachronous gastric cancer prevention ended the controversies from previous short-term studies and confirmed the effectiveness. Currently, further prospective, large, randomized studies are ongoing in the general population and will provide more definitive, high-level evidence on this gastric cancer prevention strategy in the next decade.

Keywords

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018 Sep 12. [Epub ahead of print]
  2. Jung KW, Won YJ, Kong HJ, Lee ES, Community of Population-Based Regional Cancer Registries. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat 2018;50:303-316. https://doi.org/10.4143/crt.2018.143
  3. Jun JK, Choi KS, Lee HY, et al. Effectiveness of the Korean national cancer screening program in reducing gastric cancer mortality. Gastroenterology 2017;152:1319-1328. https://doi.org/10.1053/j.gastro.2017.01.029
  4. Schistosomes, liver flukes and Helicobacter pylori. IARC working group on the evaluation of carcinogenic risks to humans, Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241.
  5. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607-615. https://doi.org/10.1016/S1470-2045(12)70137-7
  6. Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol 2014;29:1371-1386. https://doi.org/10.1111/jgh.12607
  7. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut 2017;66:6-30. https://doi.org/10.1136/gutjnl-2016-312288
  8. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017;112:212-239. https://doi.org/10.1038/ajg.2016.563
  9. Liu WZ, Xie Y, Lu H, et al. Fifth Chinese national consensus report on the management of Helicobacter pylori infection. Helicobacter 2018;23:e12475. https://doi.org/10.1111/hel.12475
  10. Mahachai V, Vilaichone RK, Pittayanon R, et al. Helicobacter pylori management in ASEAN: the Bangkok consensus report. J Gastroenterol Hepatol 2018;33:37-56. https://doi.org/10.1111/jgh.13911
  11. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 2002;16:167-180.
  12. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-194. https://doi.org/10.1001/jama.291.2.187
  13. Ma JL, Zhang L, Brown LM, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 2012;104:488-492. https://doi.org/10.1093/jnci/djs003
  14. Tsuda M, Asaka M, Kato M, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter 2017;22:e12415. https://doi.org/10.1111/hel.12415
  15. Hiroi S, Sugano K, Tanaka S, Kawakami K. Impact of health insurance coverage for Helicobacter pylori gastritis on the trends in eradication therapy in Japan: retrospective observational study and simulation study based on real-world data. BMJ Open 2017;7:e015855. https://doi.org/10.1136/bmjopen-2017-015855
  16. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015;64:1353-1367. https://doi.org/10.1136/gutjnl-2015-309252
  17. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and metaanalysis of randomised controlled trials. BMJ 2014;348:g3174. https://doi.org/10.1136/bmj.g3174
  18. Saito D, Boku N, Fujioka T, Fukuda Y, Matsushima Y, Sakaki N, et al. Impact of H. pylori eradication on gastric cancer prevention: endoscopic results of the Japanese intervention trial (JITHPstudy): a randomized multi-center trial. Gastroenterology 2005;128(suppl 2):A4. https://doi.org/10.1053/S0016-5085(04)02207-3
  19. Saito D. Present state of Japanese intervention trial of H. pylori. Nihon Rinsho 2003;61:50-55.
  20. Gail MH, You WC, Chang YS, et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Control Clin Trials 1998;19:352-369. https://doi.org/10.1016/S0197-2456(98)00016-6
  21. You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006;98:974-983. https://doi.org/10.1093/jnci/djj264
  22. Li WQ, Ma JL, Zhang L, et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. J Natl Cancer Inst 2014;106:dju116.
  23. Bang CS, Baik GH, Shin IS, et al. Helicobacter pylori eradication for prevention of metachronous recurrence after endoscopic resection of early gastric cancer. J Korean Med Sci 2015;30:749-756. https://doi.org/10.3346/jkms.2015.30.6.749
  24. Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Gastric Cancer 2018 Sep 11. [Epub ahead of print]
  25. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392-397. https://doi.org/10.1016/S0140-6736(08)61159-9
  26. Choi J, Kim SG, Yoon H, et al. Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol 2014;12:793-800. https://doi.org/10.1016/j.cgh.2013.09.057
  27. Choi JM, Kim SG, Choi J, et al. Effects of Helicobacter pylori eradication for metachronous gastric cancer prevention: a randomized controlled trial. Gastrointest Endosc 2018;88:475-485.e2. https://doi.org/10.1016/j.gie.2018.05.009
  28. Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med 2018;378:1085-1095. https://doi.org/10.1056/NEJMoa1708423
  29. Malfertheiner P. Helicobacter pylori treatment for gastric cancer prevention. N Engl J Med 2018;378:1154-1156. https://doi.org/10.1056/NEJMe1800147
  30. Gyawali B, Kesselheim AS, D'Andrea E. Does Helicobacter pylori eradication therapy to prevent gastric cancer increase all-cause mortality? Int J Cancer 2018 Aug 28. [Epub ahead of print]
  31. Boursi B, Mamtani R, Haynes K, Yang YX. Recurrent antibiotic exposure may promote cancer formation--another step in understanding the role of the human microbiota? Eur J Cancer 2015;51:2655-2664. https://doi.org/10.1016/j.ejca.2015.08.015
  32. Mima K, Nakagawa S, Sawayama H, et al. The microbiome and hepatobiliary-pancreatic cancers. Cancer Lett 2017;402:9-15. https://doi.org/10.1016/j.canlet.2017.05.001
  33. Svanstrom H, Pasternak B, Hviid A. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. BMJ 2014;349:g4930. https://doi.org/10.1136/bmj.g4930
  34. Jespersen CM, Als-Nielsen B, Damgaard M, et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006;332:22-27. https://doi.org/10.1136/bmj.38666.653600.55
  35. Gluud C, Als-Nielsen B, Damgaard M, et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology 2008;111:280-287. https://doi.org/10.1159/000128994
  36. Mosholder AD, Lee JY, Zhou EH, et al. Long-term risk of acute myocardial infarction, stroke, and death with outpatient use of clarithromycin: a retrospective cohort study. Am J Epidemiol 2018;187:786-792. https://doi.org/10.1093/aje/kwx319
  37. Root AA, Wong AY, Ghebremichael-Weldeselassie Y, et al. Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs. Br J Clin Pharmacol 2016;82:512-521. https://doi.org/10.1111/bcp.12983
  38. IARC Helicobacter pylori Working Group. Helicobacter pylori eradication as a strategy for preventing gastric cancer (IARC working group reports, No. 8). Lyon: International Agency for Research on Cancer, 2014.
  39. Herrero R, Park JY, Forman D. The fight against gastric cancer - the IARC working group report. Best Pract Res Clin Gastroenterol 2014;28:1107-1114. https://doi.org/10.1016/j.bpg.2014.10.003
  40. Pan KF, Zhang L, Gerhard M, et al. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. Gut 2016;65:9-18. https://doi.org/10.1136/gutjnl-2015-309197
  41. Leja M, Park JY, Murillo R, et al. Multicentric randomised study of Helicobacter pylori eradication and pepsinogen testing for prevention of gastric cancer mortality: the GISTAR study. BMJ Open 2017;7:e016999. https://doi.org/10.1136/bmjopen-2017-016999
  42. Tsukuma H, Oshima A, Narahara H, Morii T. Natural history of early gastric cancer: a non-concurrent, long term, follow up study. Gut 2000;47:618-621. https://doi.org/10.1136/gut.47.5.618
  43. Hamashima C, Systematic Review Group and Guideline Development Group for Gastric CancerScreening Guidelines. Update version of the Japanese Guidelines for gastric cancer screening. Jpn J Clin Oncol 2018;48:673-683. https://doi.org/10.1093/jjco/hyy077

Cited by

  1. Gastric Lesion Classification Using Deep Learning Based on Fast and Robust Fuzzy C-Means and Simple Linear Iterative Clustering Superpixel Algorithms vol.14, pp.6, 2018, https://doi.org/10.1007/s42835-019-00259-x